GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exact Sciences Corp (NAS:EXAS) » Definitions » PB Ratio

EXAS (Exact Sciences) PB Ratio : 3.99 (As of Oct. 31, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Exact Sciences PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-10-31), Exact Sciences's share price is $68.93. Exact Sciences's Book Value per Share for the quarter that ended in Jun. 2024 was $17.29. Hence, Exact Sciences's PB Ratio of today is 3.99.

The historical rank and industry rank for Exact Sciences's PB Ratio or its related term are showing as below:

EXAS' s PB Ratio Range Over the Past 10 Years
Min: 1.69   Med: 5.7   Max: 20.42
Current: 3.99

During the past 13 years, Exact Sciences's highest PB Ratio was 20.42. The lowest was 1.69. And the median was 5.70.

EXAS's PB Ratio is ranked worse than
76.24% of 202 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.32 vs EXAS: 3.99

During the past 12 months, Exact Sciences's average Book Value Per Share Growth Rate was 2.10% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 7.30% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 19.90% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 28.10% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Exact Sciences was 107.80% per year. The lowest was -45.60% per year. And the median was 7.60% per year.

Back to Basics: PB Ratio


Exact Sciences PB Ratio Historical Data

The historical data trend for Exact Sciences's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exact Sciences PB Ratio Chart

Exact Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.97 9.45 3.99 2.89 4.27

Exact Sciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.55 3.95 4.27 4.05 2.44

Competitive Comparison of Exact Sciences's PB Ratio

For the Diagnostics & Research subindustry, Exact Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exact Sciences's PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Exact Sciences's PB Ratio distribution charts can be found below:

* The bar in red indicates where Exact Sciences's PB Ratio falls into.



Exact Sciences PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Exact Sciences's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2024)
=68.93/17.287
=3.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Exact Sciences  (NAS:EXAS) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Exact Sciences PB Ratio Related Terms

Thank you for viewing the detailed overview of Exact Sciences's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Exact Sciences Business Description

Traded in Other Exchanges
Address
5505 Endeavor Lane, Madison, WI, USA, 53719
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, or MRD, colorectal cancer screening, and multicancer screening.
Executives
Brian Baranick officer: Gen. Mgr., Precision Oncology 441 CHARMANY DRIVE, MADISON WI 53719
Jacob A Orville officer: General Manager, New Ventures 5505 ENDEAVOR LANE, MADISON WI 53719
James Herriott officer: General Counsel 5505 ENDEAVOR LANE, MADISON WI 53719
Sarah Condella officer: SVP, Human Resources 441 CHARMANY DRIVE, MADISON WI 53719
D Scott Coward officer: SVP and General Counsel 441 CHARMANY DRIVE, MADISON WI 53719
Jeffrey Thomas Elliott officer: Chief Financial Officer 5505 ENDEAVOR LANE, MADISON WI 53719
Kevin T Conroy director, officer: Vice President 5505 ENDEAVOR LANE, MADISON WI 53719
Everett Cunningham officer: Chief Commercial Officer C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Daniel J Levangie director 85 SWANSON ROAD, BOXBOROUGH MA 01719
James Edward Doyle director 5505 ENDEAVOR LANE, MADISON WI 53719
Timothy J Scannell director 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Katherine S Zanotti director 431 E 9TH STREET, HINSDALE IL 60521
Paul J Clancy director C/O BIOGEN IDEC INC., 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Graham Peter Lidgard officer: SVP, Chief Scientific Officer 5505 ENDEAVOR LANE, MADISON WI 53719
Michael S Wyzga director RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02139